EX-99.1 2 veco-20240214xex99d1.htm EX-99.1

EXHIBIT 99.1

Graphic

VEECO REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS

Fourth Quarter 2023 Highlights:

Revenue of $173.9 million, compared with $153.8 million in the same period last year
GAAP net income of $21.6 million, or $0.37 per diluted share, compared with $128.9 million, or $2.00 per diluted share in the same period last year
Non-GAAP net income of $29.8 million, or $0.51 per diluted share, compared with $21.9 million, or $0.38 per diluted share in the same period last year

Fiscal Year 2023 Highlights:

Revenue of $666.4 million, compared with $646.1 million in the same period last year
GAAP net loss of $30.4 million, or $0.56 loss per diluted share, included a $97.1 million loss related to debt refinancing, compared with net income of $166.9 million, or $2.71 earnings per diluted share in the same period last year
Non-GAAP net income of $98.3 million, or $1.69 per diluted share, compared with $89.6 million, or $1.57 per diluted share in the same period last year

Plainview, N.Y., February 14, 2024 -- Veeco Instruments Inc. (Nasdaq: VECO) today announced financial results for its fourth quarter and fiscal year ended December 31, 2023. Results are reported in accordance with U.S. generally accepted accounting principles (“GAAP”) and are also reported adjusting for certain items (“Non-GAAP”). A reconciliation between GAAP and Non-GAAP operating results is provided at the end of this press release.  

U.S. Dollars in millions, except per share data

4th Quarter

Full Year

GAAP Results

 

Q4 '23

Q4 '22

2023

   

2022

Revenue

$

173.9

$

153.8

$

666.4

$

646.1

Net income (loss)

$

21.6

$

128.9

$

(30.4)

$

166.9

Diluted earnings (loss) per share

$

0.37

$

2.00

$

(0.56)

$

2.71

4th Quarter

Full Year

Non-GAAP Results

 

Q4 '23

Q4 '22

2023

2022

Operating income

$

32.1

$

23.8

$

109.6

$

99.8

Net income

$

29.8

$

21.9

$

98.3

$

89.6

Diluted earnings per share

$

0.51

$

0.38

$

1.69

$

1.57

“2023 was a critical year for Veeco, highlighted by our Semiconductor business outperforming WFE growth for the 3rd consecutive year,” commented Bill Miller, Ph.D., Veeco’s Chief Executive Officer. “I’m proud to say we successfully grew the business, improved profitability, and most importantly, laid the groundwork for future growth. We achieved a significant milestone by shipping evaluation systems for two important core technologies in Nanosecond Annealing and Ion Beam Deposition. These technologies enable our customers to fabricate devices that enable higher performance and reduced power consumption.”

1


Guidance and Outlook

The following guidance is provided for Veeco’s first quarter 2024:

Revenue is expected in the range of $160 million to $180 million
GAAP diluted earnings per share are expected in the range of $0.22 to $0.33
Non-GAAP diluted earnings per share are expected in the range of $0.36 to $0.46

Conference Call Information

A conference call reviewing these results has been scheduled for today, February 14, 2024 starting at 5:00pm ET. To join the call, dial 1-877-407-8029 (toll-free) or 1-201-689-8029. Participants may also access a live webcast of the call by visiting the investor relations section of Veeco's website at ir.veeco.com. A replay of the webcast will be made available on the Veeco website that evening. We will post an accompanying slide presentation to our website prior to the beginning of the call.

About Veeco

Veeco (NASDAQ: VECO) is an innovative manufacturer of semiconductor process equipment. Our laser annealing, ion beam, chemical vapor deposition (CVD), metal organic chemical vapor deposition (MOCVD), single wafer etch & clean and lithography technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco’s systems and service offerings, visit www.veeco.com.

Forward-looking Statements

This press release contains “forward-looking statements”, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended, that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, those regarding anticipated growth and trends in our businesses and markets, industry outlooks and demand drivers, our investment and growth strategies, our development of new products and technologies, our business outlook for current and future periods, our ongoing transformation initiative and the effects thereof on our operations and financial results; and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the level of demand for our products; global economic and industry conditions; global trade issues, including the ongoing trade disputes between the U.S. and China, and changes in trade and export license policies; our dependency on third-party suppliers and outsourcing partners; the timing of customer orders; our ability to develop, deliver and support new products and technologies; our ability to expand our current markets, increase market share and develop new markets; the concentrated nature of our customer base; our ability to obtain and protect intellectual property rights in key technologies; the effects of regional or global health epidemics, including the effects of the COVID-19 pandemic on the Company’s operations and on those of our customers and suppliers; our ability to achieve the objectives of operational and strategic initiatives and attract, motivate and retain key employees; the variability of results among products and end-markets, and our ability to accurately forecast future results, market conditions, and customer requirements; the impact of our indebtedness, including our convertible senior notes and our capped call transactions; and other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q and 8-K, and from time-to-time in our other SEC reports. All forward-looking statements speak only to management’s expectations, estimates, projections and assumptions as of the date of this press release or, in the case of any document referenced herein or incorporated by reference, the date of that document. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.

-financial tables attached-

Veeco Contacts:

Investors:Anthony Pappone (516) 500-8798apappone@veeco.com

Media:Kevin Long (516) 714-3978klong@veeco.com

2


Veeco Instruments Inc. and Subsidiaries
Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)
(unaudited)

Three months ended December 31,

Year ended December 31,

 

    

2023

    

2022

    

2023

    

2022

 

Net sales

 

$

173,924

 

$

153,799

 

$

666,435

 

$

646,137

Cost of sales

 

95,269

 

90,881

 

381,376

 

382,989

Gross profit

 

78,655

 

62,918

 

285,059

 

263,148

Operating expenses, net:

Research and development

 

29,091

 

26,327

 

112,853

 

103,565

Selling, general, and administrative

 

23,493

 

20,965

 

92,756

 

88,952

Amortization of intangible assets

 

2,123

 

2,505

 

8,481

 

10,018

Other operating expense (income), net

 

(235)

 

(271)

 

1,029

 

317

Total operating expenses, net

 

54,472

 

49,526

 

215,119

 

202,852

Operating income

 

24,183

 

13,392

 

69,940

 

60,296

Interest expense, net

 

 

(1,558)

 

(1,187)

 

(9,311)

Other income (expense), net

(97,091)

Income (loss) before income taxes

 

24,183

 

11,834

 

(28,338)

 

50,985

Income tax expense (benefit)

 

2,546

 

(117,081)

 

2,030

 

(115,957)

Net income (loss)

 

$

21,637

 

$

128,915

 

$

(30,368)

 

$

166,942

Income (loss) per common share:

Basic

 

$

0.39

 

$

2.58

 

$

(0.56)

 

$

3.35

Diluted

 

$

0.37

 

$

2.00

 

$

(0.56)

 

$

2.71

Weighted average number of shares:

Basic

 

55,537

 

49,912

 

53,769

 

49,906

Diluted

 

59,821

 

65,684

 

53,769

 

65,607

3


Veeco Instruments Inc. and Subsidiaries
Condensed Consolidated Balance Sheets

(in thousands)

December 31,

December 31,

    

2023

    

2022

(unaudited)

Assets

Current assets:

Cash and cash equivalents

$

158,781

$

154,925

Restricted cash

 

339

 

547

Short-term investments

 

146,664

 

147,488

Accounts receivable, net

 

103,018

 

124,221

Contract assets

 

24,370

 

16,507

Inventories

 

237,635

 

206,908

Prepaid expenses and other current assets

 

35,471

 

18,305

Total current assets

 

706,278

 

668,901

Property, plant and equipment, net

 

118,459

 

107,281

Operating lease right-of-use assets

24,377

 

26,467

Intangible assets, net

 

43,945

 

23,887

Goodwill

 

214,964

 

181,943

Deferred income taxes

 

117,901

 

116,349

Other assets

 

3,117

 

3,355

Total assets

$

1,229,041

$

1,128,183

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

42,383

$

52,049

Accrued expenses and other current liabilities

 

57,624

 

56,031

Contract liabilities

 

118,026

 

127,223

Income taxes payable

 

 

2,432

Current portion of long-term debt

20,169

Total current liabilities

 

218,033

 

257,904

Deferred income taxes

 

6,552

 

1,285

Long-term debt

 

274,941

 

254,491

Long-term operating lease liabilities

31,529

 

33,581

Other liabilities

 

25,544

 

3,098

Total liabilities

 

556,599

 

550,359

Total stockholders’ equity

 

672,442

 

577,824

Total liabilities and stockholders’ equity

$

1,229,041

$

1,128,183

Note on Reconciliation Tables

The below tables include financial measures adjusted for the impact of certain items; these financial measures are therefore not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These Non-GAAP financial measures exclude items such as: share-based compensation expense; charges relating to restructuring initiatives; non-cash asset impairments; certain other non-operating gains and losses; and acquisition-related items such as transaction costs, non-cash amortization of acquired intangible assets, and certain integration costs.

These Non-GAAP financial measures may be different from Non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. By excluding these items, Non-GAAP financial measures are intended to facilitate meaningful comparisons to historical operating results, competitors’ operating results, and estimates made by securities analysts. Management is evaluated on key performance metrics including Non-GAAP Operating income (loss), which is used to determine management incentive compensation as well as to forecast future periods. These Non-GAAP financial measures may be useful to investors in allowing for greater transparency of supplemental information used by management in its financial and operational decision-making. In addition, similar Non-GAAP financial measures have historically been reported to investors; the inclusion of comparable numbers provides consistency in financial reporting. Investors are encouraged to review the reconciliation of the Non-GAAP financial measures used in this news release to their most directly comparable GAAP financial measures.

4


Reconciliation of GAAP to Non-GAAP Financial Data (Q4 2023)

(in thousands)
(unaudited)

Non-GAAP Adjustments

 

Share-Based

 

Three months ended December 31, 2023

    

GAAP

    

Compensation

    

Amortization

    

Other

    

Non-GAAP

 

Net sales

$

173,924

$

173,924

 

Gross profit

 

78,655

 

334

 

 

78,989

Gross margin

 

45.2

%

 

45.4

%

Operating expenses

 

54,472

 

(5,845)

(2,123)

363

46,867

Operating income

 

24,183

 

6,179

2,123

 

(363)

^

32,122

Net income

 

21,637

 

6,179

 

2,123

 

(116)

^

29,823


^

- See table below for additional details.

Other Non-GAAP Adjustments (Q4 2023)

(in thousands)
(unaudited)

Three months ended December 31, 2023

    

Changes in contingent consideration

$

(465)

Other

102

Subtotal

(363)

Non-cash interest expense

 

294

Non-GAAP tax adjustment *

 

(47)

Total Other

$

(116)


*

- The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

Net Income per Common Share (Q4 2023)

(in thousands, except per share amounts)
(unaudited)

Three months ended December 31, 2023

GAAP

Non-GAAP

Numerator:

Net income

    

$

21,637

    

$

29,823

Interest expense associated with 2025 and 2027 Convertible Senior Notes

 

511

 

 

466

Net income available to common shareholders

$

22,148

$

30,289

Denominator:

Basic weighted average shares outstanding

55,537

55,537

Effect of potentially dilutive share-based awards

1,391

1,391

Dilutive effect of 2025 Convertible Senior Notes

1,104

1,104

Dilutive effect of 2027 Convertible Senior Notes (1)

 

1,789

 

 

1,355

Diluted weighted average shares outstanding

59,821

59,387

Net income per common share:

Basic

$

0.39

$

0.54

Diluted

$

0.37

$

0.51


(1)  -  The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

5


Reconciliation of GAAP to Non-GAAP Financial Data (Q4 2022)

(in thousands, except per share amounts)
(unaudited)

Non-GAAP Adjustments

 

Share-based

Three months ended December 31, 2022

    

GAAP

    

Compensation

    

Amortization

    

Other

    

Non-GAAP

Net sales

$

153,799

$

153,799

Gross profit

 

62,918

 

1,167

 

1,011

 

65,096

Gross margin

 

40.9

%  

42.3

%

Operating expenses

 

49,526

 

(4,858)

(2,505)

(821)

41,342

Operating income

 

13,392

 

6,025

2,505

 

1,832

^

23,754

Net income

 

128,915

 

6,025

 

2,505

 

(115,554)

^

21,891


^

- See table below for additional details.

Other Non-GAAP Adjustments (Q4 2022)

(in thousands)
(unaudited)

Three months ended December 31, 2022

Transition expenses related to San Jose expansion project

$

1,788

Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting

44

Subtotal

1,832

Non-cash interest expense

 

244

Release of valuation allowance on deferred tax assets

(104,971)

Non-GAAP tax adjustment *

 

(12,659)

Total Other

$

(115,554)


*

- The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

Net Income per Common Share (Q4 2022)

(in thousands, except per share amounts)
(unaudited)

Three months ended December 31, 2022

GAAP

Non-GAAP

Numerator:

Net income

    

$

128,915

    

$

21,891

Interest expense associated with convertible notes

 

2,712

 

 

2,467

Net income available to common shareholders

$

131,627

$

24,358

Denominator:

Basic weighted average shares outstanding

49,912

49,912

Effect of potentially dilutive share-based awards

805

805

Dilutive effect of 2023 Convertible Senior Notes

504

504

Dilutive effect of 2025 Convertible Senior Notes

5,521

5,521

Dilutive effect of 2027 Convertible Senior Notes (1)

 

8,942

 

 

6,771

Diluted weighted average shares outstanding

65,684

63,513

Net income per common share:

Basic

$

2.58

$

0.44

Diluted

$

2.00

$

0.38


(1)    - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

6


Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q4 2023 and 2022)

(in thousands)
(unaudited)

    

Three months ended

    

Three months ended

December 31, 2023

December 31, 2022

GAAP Net income

$

21,637

$

128,915

Share-based compensation

 

6,179

 

6,025

Amortization

 

2,123

 

2,505

Transition expenses related to San Jose expansion project

 

57

 

1,788

Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting

 

 

44

Changes in contingent consideration

(465)

Acquisition related

 

45

 

Interest (income) expense, net

 

 

1,558

Income tax expense (benefit)

 

2,546

 

(117,081)

Non-GAAP Operating income

$

32,122

$

23,754

Reconciliation of GAAP to Non-GAAP Financial Data (FY 2023)

(in thousands)
(unaudited)

Non-GAAP Adjustments

 

Share-based

For the year ended December 31, 2023

    

GAAP

    

Compensation

    

Amortization

    

Other

    

Non-GAAP

Net sales

$

666,435

$

666,435

Gross profit

 

285,059

 

4,913

 

232

 

290,204

Gross margin

 

42.8

%  

43.5

%

Operating expenses

 

215,119

 

(23,645)

(8,481)

(2,363)

180,630

Operating income

 

69,940

 

28,558

8,481

 

2,595

^

109,574

Net income (loss)

 

(30,368)

 

28,558

 

8,481

 

91,668

^

98,339


^

- See table below for additional details.

Other Non-GAAP Adjustments (FY 2023)

(in thousands)
(unaudited)

For the year ended December 31, 2023

    

Acquisition related

$

1,056

Changes in contingent consideration

 

701

Transition expenses related to San Jose expansion project

838

Subtotal

2,595

Non-cash interest expense

 

1,118

Other (income) expense, net

97,091

Non-GAAP tax adjustment *

 

(9,136)

Total Other

$

91,668


*

- The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

7


Net Income per Common Share (FY 2023)

(in thousands, except per share amounts)
(unaudited)

Year ended December 31, 2023

GAAP

Non-GAAP

Numerator:

Net income (loss)

    

$

(30,368)

    

$

98,339

Interest expense associated with convertible notes

 

 

 

4,768

Net income (loss) available to common shareholders

$

(30,368)

$

103,107

Denominator:

Basic weighted average shares outstanding

53,769

53,769

Effect of potentially dilutive share-based awards

850

Dilutive effect of 2023 Convertible Senior Notes

21

Dilutive effect of 2025 Convertible Senior Notes

2,786

Dilutive effect of 2027 Convertible Senior Notes (1)

 

 

 

3,417

Diluted weighted average shares outstanding

53,769

60,843

Net income (loss) per common share:

Basic

$

(0.56)

$

1.83

Diluted

$

(0.56)

$

1.69


(1)    - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

Reconciliation of GAAP to Non-GAAP Financial Data (FY 2022)

(in thousands)
(unaudited)

Non-GAAP Adjustments

 

Share-based

For the year ended December 31, 2022

    

GAAP

    

Compensation

    

Amortization

    

Other

    

Non-GAAP

Net sales

$

646,137

$

646,137

Gross profit

 

263,148

 

4,551

 

3,300

 

270,999

Gross margin

 

40.7

%  

41.9

%

Operating expenses

 

202,852

 

(18,443)

(10,018)

(3,212)

171,179

Operating income

 

60,296

 

22,994

10,018

 

6,512

^

99,820

Net income

 

166,942

 

22,994

 

10,018

 

(110,379)

^

89,575


^

- See table below for additional details.

8


Other Non-GAAP Adjustments (FY 2022)

(in thousands)
(unaudited)

For the year ended December 31, 2022

Transition expenses related to San Jose expansion project

$

6,202

Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting

310

Subtotal

6,512

Non-cash interest expense

962

Other (income) expense, net

(104,971)

Non-GAAP tax adjustment *

 

(12,882)

Total Other

$

(110,379)


*

- The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

Net Income per Common Share (FY 2022)

(in thousands, except per share amounts)
(unaudited)

Year ended December 31, 2022

GAAP

Non-GAAP

Numerator:

Net income

    

$

166,942

    

$

89,575

Interest expense associated with convertible notes

 

10,832

 

 

9,870

Net income available to common shareholders

$

177,774

$

99,445

Denominator:

Basic weighted average shares outstanding

49,906

49,906

Effect of potentially dilutive share-based awards

734

734

Dilutive effect of 2023 Convertible Senior Notes

504

504

Dilutive effect of 2025 Convertible Senior Notes

5,521

5,521

Dilutive effect of 2027 Convertible Senior Notes (1)

 

8,942

 

 

6,771

Diluted weighted average shares outstanding

65,607

63,436

Net income per common share:

Basic

$

3.35

$

1.79

Diluted

$

2.71

$

1.57


(1)    - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

9


Reconciliation of GAAP Net Income to Non-GAAP Operating Income (FY 2023 and 2022)

(in thousands)
(unaudited)

    

Year ended

    

Year ended

December 31, 2023

December 31, 2022

GAAP Net income (loss)

$

(30,368)

$

166,942

Share-based compensation

 

28,558

 

22,994

Amortization

 

8,481

 

10,018

Acquisition related

1,056

Changes in contingent consideration

 

701

 

Transition expenses related to San Jose expansion project

 

838

 

6,202

Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting

 

 

310

Interest (income) expense, net

 

1,187

 

9,311

Other (income) expense, net

97,091

Income tax expense (benefit)

 

2,030

 

(115,957)

Non-GAAP Operating income (loss)

$

109,574

$

99,820

Reconciliation of GAAP to Non-GAAP Financial Data (Q1 2024)

(in millions, except per share amounts)

(unaudited)

Non-GAAP Adjustments

 

Guidance for the three months ending

Share-based

 

March 31, 2024

GAAP

Compensation

Amortization

   Other    

Non-GAAP

 

Net sales

    

$

160

    

-

    

$

180

    

    

    

    

$

160

    

-

    

$

180

Gross profit

 

68

 

-

 

78

 

1

 

 

 

69

 

-

 

79

Gross margin

 

42%

-

 

43%

 

 

 

43%

-

 

44%

Operating expenses

53

 

-

 

56

(6)

(2)

46

 

-

 

48

Operating income

15

-

22

7

2

24

-

31

Net income

$

13

 

-

$

20

 

7

 

2

(1)

$

21

 

-

$

27

Income per diluted common share

$

0.22

 

-

$

0.33

 

  

 

  

 

  

$

0.36

 

-

$

0.46

10


Income per Diluted Common Share (Q1 2024)

(in millions, except per share amounts)
(unaudited)

Guidance for the three months ending March 31, 2024

GAAP

Non-GAAP

Numerator:

Net income

    

$

13

    

-

    

$

20

    

$

21

    

-

    

$

27

Interest expense associated with convertible notes

 

 

 

 

 

 

 

Net income available to common shareholders

$

13

-

$

20

$

21

-

$

27

Denominator:

Basic weighted average shares outstanding

56

56

56

56

Effect of potentially dilutive share-based awards

1

 

1

1

 

1

Dilutive effect of 2025 Convertible Senior Notes

1

1

1

Dilutive effect of 2027 Convertible Senior Notes (1)

2

 

2

 

1

 

1

Dilutive effect of 2029 Convertible Senior Notes

 

1

 

1

 

 

1

 

1

Diluted weighted average shares outstanding

60

61

60

60

Net income per common share:

Income per diluted common share

$

0.22

-

$

0.33

$

0.36

-

$

0.46


(1)    - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q1 2024)

(in millions)
(unaudited)

Guidance for the three months ending March 31, 2024

    

    

    

GAAP Net income

$

13

 

-

$

20

Share-based compensation

 

7

 

-

 

7

Amortization

 

2

 

-

 

2

Income tax expense (benefit)

2

-

2

Non-GAAP Operating income

$

24

 

-

$

31

Note: Amounts may not calculate precisely due to rounding.

11